Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Revefenacin

FDA-approved product (solution, inhalation), marketed as Yupelri.

Registered studies
20
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Revefenacin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Airway obstruction
  • Chronic obstructive pulmonary disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anticholinergics
FDA pharmacologic class
Anticholinergic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

20registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Revefenacin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Revefenacin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

    NCT02772159 · start 2015-06

    Registered record
    Registry ID
    NCT02772159
    Conditions
    Chronic Obstructive Pulmonary Disease (COPD)
    Interventions
    TD-4208
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-06
    Completion
    2016-04
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease (COPD)
    InterventionTD-4208
    PhasePhase 1
    Registry statusCompleted

  • A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

    NCT02040792 · start 2014-05

    Registered record
    Registry ID
    NCT02040792
    Conditions
    COPD
    Interventions
    TD-4208; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-05
    Completion
    2014-08
    Enrolment
    355

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD
    InterventionTD-4208; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

    NCT02109172 · start 2014-04

    Registered record
    Registry ID
    NCT02109172
    Conditions
    Chronic Obstructive Pulmonary Disease; COPD
    Interventions
    TD-4208; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-04
    Completion
    2014-10
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease; COPD
    InterventionTD-4208; Placebo
    PhasePhase 2
    Registry statusCompleted

  • 7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

    NCT01704404 · start 2012-12

    Registered record
    Registry ID
    NCT01704404
    Conditions
    COPD
    Interventions
    TD-4208; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-12
    Completion
    2013-12
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD
    InterventionTD-4208; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

    NCT03064113 · start 2011-05

    Registered record
    Registry ID
    NCT03064113
    Conditions
    Chronic Obstructive Pulmonary Disease, COPD
    Interventions
    Placebo; TD-4208 700 μg; TD-4208 350 μg; Ipratropium 500 μg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-05
    Completion
    2011-10
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease, COPD
    InterventionPlacebo; TD-4208 700 μg; TD-4208 350 μg; Ipratropium 500 μg
    PhasePhase 2
    Registry statusCompleted